News - Sobi

Filter

Current filters:

Sobi

Popular Filters

Swedish company Dilaforette announces Sobi’s Christina Herder as new CEO

22-01-2014

Swedish drug development company Dilaforette has named Christina Herder as its new chief executive.

BoardroomDilaforetteHematologyNorthern EuropePharmaceuticalSobi

Sobi terminates deal with Rare Disease Therapeutics for Orfadin distribution

Sobi terminates deal with Rare Disease Therapeutics for Orfadin distribution

20-12-2013

Nordic biotech firm Swedish Orphan Biovitrum (STO: SOBI) has terminated its distributor agreement with…

BiotechnologyLegalLicensingNorthern EuropeOrfadinRare Disease TherapeuticsSobi

Pediatric indication for SOBI’s Kineret from UK’s MHRA

Pediatric indication for SOBI’s Kineret from UK’s MHRA

18-12-2013

Kineret (anakinra), from Nordic biotech firm Swedish Orphan Biovitrum (STO: SOBI), has been licensed…

BiotechnologyImmunologicalsKineretRegulationSobiUK

ASH 2013: Meeting highlights from Novartis, Takeda, Biogen Idec and SOBI

ASH 2013: Meeting highlights from Novartis, Takeda, Biogen Idec and SOBI

10-12-2013

This year’s American Society of Hematology (ASH) meeting continued yesterday with more clinical trial…

Biogen IdecEloctateHematologyJakaviNovartisPharmaceuticalResearchSobiTakeda PharmaceuticalsUSA

Biogen and SOBI announce top line results for hemophilia A treatment Eloctate

Biogen and SOBI announce top line results for hemophilia A treatment Eloctate

14-11-2013

US biotech major Biogen Idec (Nasdaq: BIIB) and Swedish Orphan Biovitrum (STO: SOBI) have announced detailed…

Biogen IdecBiotechnologyEloctateHematologyNorth AmericaResearchSobiUSA

SOBI updates on Kepivance and SOB1002 development

SOBI updates on Kepivance and SOB1002 development

05-11-2013

At its Capital Market Day event on November 5, Swedish Orphan Biovitrum shared information regarding…

Inflammatory diseasesKepivanceKiobrinaOncologyPharmaceuticalResearchSOB1002SobiSwedish Orphan Biovitrum

SOBI reveals strong sales in third quarter

SOBI reveals strong sales in third quarter

30-10-2013

Swedish Orphan Biovitrum has published its third quarter results revealing that total revenues were 517.3…

EuropeFinancialKineretOrfadinPharmaceuticalSobi

SOBI gains rights to distribute Ravicti in Middle East

01-10-2013

Swedish Orphan Biovitrum says Hyperion Therapeutics has granted it exclusive rights to distribute its…

Genito-urinaryHyperion TherapeuticsLicensingPharmaceuticalRavictiRest of the WorldSobiSwedish Orphan Biovitrum

New data supports safety of Biogen and SOBI's Eloctate for hemophilia A

05-07-2013

US biotech firm Biogen Idec (Nasdaq: BIIB) and Stockholm-based Swedish Orphan Biovitrum (STO: SOBI) have…

AlprolixBiogen IdecEloctatePharmaceuticalResearchSobi

SOBI to distribute Exelixis' cancer drug Cometriq in EU

22-02-2013

US biotech firm Exelixis (Nasdaq: EXEL) has entered into a three-year with Swedish Orphan Biovitrum (STO:…

BiotechnologyCometriqEuropeExelixisLicensingOncologySobiSwedish Orphan Biovitrum

FDA approves SOBI's Kineret for the treatment of NOMID

08-01-2013

Biotech firm Swedish Orphan Biovitrum (STO: SOBI) today announced that the US Food and Drug Administration…

AmgenBiotechnologyInflammatory diseasesKineretNorth AmericaRegulationSobiSwedish Orphan Biovitrum

Back to top